Eli Lil­ly hands transpa­cif­ic biotech up­start Terns pieces to an ex­per­i­men­tal NASH puz­zle

Wei­dong Zhong

For Wei­dong Zhong, the fastest part of start­ing up a transpa­cif­ic biotech was find­ing the mon­ey.

Al­most im­me­di­ate­ly af­ter step­ping out of No­var­tis’ ear­ly-stage re­search group a year ago, the long­time in­ves­ti­ga­tor with a back­ground that in­cludes a stint in­volv­ing liv­er dis­eases at Gilead had the en­thu­si­as­tic back­ing of Lil­ly Asia Ven­tures, a busy ven­ture group which pro­vid­ed the $30 mil­lion need­ed to get go­ing.

“They very much liked the idea,” Zhong tells me. “We didn’t even have time to dis­close that (Se­ries A) be­cause every­thing hap­pened so quick­ly.”

Now, the rest of it is com­ing to­geth­er quick­ly as well, with a pipeline that’s be­ing swelled to­day by an in-li­cens­ing deal with Eli Lil­ly de­liv­er­ing three pro­grams for NASH. So it’s a good time, Zhong feels, to make the de­but they had missed a year ago.

The ba­sic idea at Terns Phar­ma­ceu­ti­cals was that a Cal­i­for­nia-based dis­cov­ery team al­lied with a small de­vel­op­ment group in Chi­na could as­sem­ble a pipeline and ef­fi­cient­ly de­vel­op new drugs pri­mar­i­ly for the Chi­nese mar­ket.

“We can short­en the time it takes to de­vel­op drugs for the Chi­na mar­ket,” says the CEO, who feels they are well po­si­tioned to trans­late the rapid­ly im­prov­ing reg­u­la­to­ry process in Chi­na. Eli Lil­ly plans to learn from their progress.

With an in­tro from their col­leagues at Lil­ly Asia Ven­tures, they were able to ink an agree­ment with the moth­er com­pa­ny that cov­ers a clin­i­cal-stage far­ne­soid X re­cep­tor (FXR) ag­o­nist, TERN-101, a semi­car­bazide-sen­si­tive amine ox­i­dase (SSAO) in­hibitor, TERN-201 — which is near­ing IND sub­mis­sion — and an undis­closed pre­clin­i­cal can­di­date. And they are com­bin­ing the NASH work with on­col­o­gy, build­ing on the 5 pro­grams pieced to­geth­er by their in-house group in Shang­hai.

101 seems well de­signed to ad­vance in Chi­na, says the sci­en­tist, as the var­i­ous play­ers be­gin to as­sem­ble the unique com­bi­na­tions that he be­lieves will be need­ed to ad­dress var­i­ous stages of NASH, as well as pos­si­bly dif­fer­ent ge­net­ic groups. 201, though, he be­lieves has the kind of first-in-class po­ten­tial that they could work on for both the US and the Chi­nese mar­kets si­mul­ta­ne­ous­ly.

The move to out li­cense drugs point­ed pri­mar­i­ly to Chi­na comes about a year af­ter Lil­ly opt­ed to shut down its R&D base in Shang­hai, fol­low­ing a pat­tern of big phar­ma ex­its that al­so in­clud­ed GSK. Lil­ly now is fo­cus­ing on al­liances like this one to ad­vance new drugs in the boom­ing Asian mar­ket.

Zhong likes the idea of go­ing back in­to liv­er dis­eases and match­ing it with on­col­o­gy as a good way of dis­tin­guish­ing the start­up in a boom­ing Chi­nese biotech field. And he has every in­ten­tion of stay­ing in the fast lane.

Their pro­jec­tion for the SSAO drug is to get it in­to the clin­ic in ear­ly 2019, with a shot at com­plet­ing the proof-of-con­cept stage in 2021 that could — if every­thing works out — leave them on the thresh­old of a late-stage pro­gram.

That’s am­bi­tious for a com­pa­ny that cur­rent­ly to­tals about 15 full timers, plus CRO help. But Zhong feels that the com­pa­ny can op­er­ate like the small, tough lit­tle wa­ter bird it’s named af­ter, built for long mi­gra­tions. 

They may be small, but Terns plans to go far.

RWE chal­lenges for to­day's bio­phar­ma

The rapid development of technology — and the resulting avalanche of data — are catalysts for significant change in the biopharmaceutical industry. This translates into urgent pressures for today’s biopharma, including a need to quickly and affordably develop products with proven therapeutic efficacy and value. This urgency is expedited by the growth of value-based contracting, where access to reimbursement and profit depends on these abilities.

UP­DAT­ED: In a stun­ning turn­around, Bio­gen says that ad­u­canum­ab does work for Alzheimer's — but da­ta min­ing in­cites con­tro­ver­sy and ques­tions

Biogen has confounded the biotech world one more time.

In a stunning about-face, the company and its partners at Eisai say that a new analysis of a larger dataset on aducanumab has restored its faith in the drug as a game-changer for Alzheimer’s and, after talking it over with the FDA, they’ll now be filing for an approval of a drug that had been given up for dead.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 63,100+ biopharma pros reading Endpoints daily — and it's free.

As shares suf­fer from a lin­ger­ing slump, a bruised Alk­er­mes slash­es 160 jobs in R&D re­struc­tur­ing

With its share price in a deep slump after suffering through a regulatory debacle over their depression drug ALKS 5461, Alkermes CEO Richard Pops is taking the ax to its R&D organization in a restructuring aimed at cutting costs ahead of its next attempt at a rollout in a tough field.

Richard Pops, Endpoints via Youtube

Click on the image to see the full-sized version

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 63,100+ biopharma pros reading Endpoints daily — and it's free.

Acor­da's Ron Co­hen brings the ax back out as new drug sales on­ly trick­le in while cash cow is led to the slaugh­ter

With its new drug earning meager sums and its one-time cash cow reduced to a bony shadow of its former self, Acorda Therapeutics today is rolling out a new restructuring aimed at slashing the staff and cutting costs to get through the hard times ahead.

The biotech is chopping a quarter of its staff today, carving back R&D as well as SG&A expenses. And CEO Ron Cohen is cutting deep.

Under the new austerity budget, Acorda’s R&D expenses for the full year 2019 are expected to be $55 – $60 million, reduced from $70 – $80 million. SG&A expenses for the full year 2019 are expected to be $185 – $190 million, reduced from $200 – $210 million. R&D expenses for the full year 2020 are expected to be $20 – $25 million and SG&A
expenses for the full year 2020 are expected to be $160 – $165 million.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 63,100+ biopharma pros reading Endpoints daily — and it's free.

RAPT Ther­a­peu­tics re­turns to Wall Street to re­vive IPO bid

On May 24, FLX Bio, a small cancer and inflammation biotech with backing from GV, changed its name to RAPT Therapeutics and filed confidentially for an IPO. On July 5th, they filed to raise up to $86 million. On July 22, they announced the IPO with a $75 million goal.  And on August 1, they abruptly and without explanation called it all off.

Now, without explanation, they’re reviving the bid, filing again for a $75 million IPO, this time with a new bookrunner and a new drug candidate in the clinic. The terms will be the same: 5 million shares at $14-$16 per share. It would give them a diluted market value of $351 million.

EY vet set to re­place re­tir­ing Am­gen CFO Meline

Ahead of its third-quarter results next week, Amgen on Tuesday disclosed the planned retirement of David Meline, who has served as the company’s chief financial officer since 2014.

Meline will be replaced by Ernst & Young vet, Peter Griffith, as CFO come January 1, 2020 — but until then Griffith will serve as executive vice president, finance.

“Over the last 5 years at Amgen, Meline instituted many major changes that led to operational efficiencies and margin expansion while successfully returning cash to shareholders. Now that Amgen is on solid footing, it was a good time to step away,” Cowen’s Yaron Werber wrote in a note. “We do not anticipate any major changes to strategy or operations immediately due to this transition as Amgen is on solid footing.”

Eli Lil­ly’s USA, di­a­betes chief En­rique Con­ter­no is head­ing out af­ter 27 years, and he’s be­ing re­placed by a com­pa­ny in­sid­er

Close to 3 years after Eli Lilly CEO Dave Ricks added the title of president of the US operations to Enrique Conterno’s resume, which included his helmsmanship of the diabetes franchise, the Peruvian born exec is set to retire after a 27-year run at the pharma giant.

Lilly put out the news just as it was posting Q3 results, with a mix of upbeat and downbeat results in the latest set of numbers from Lilly.
Conterno — a grizzled, deeply experienced and sometimes gruff veteran of the pharma world — was a high-profile figure at Lilly, stepping up to expanded duties as the company was forced to deal with intense pricing pressure on the diabetes side of the business. He had replaced outgoing US president Alex Azar, who later popped up as head of Health and Human Services in the Trump administration.
As head of the diabetes unit, Conterno had to deal with an extraordinarily competitive field as payers demanded bigger discounts. Trulicity’s success helped generate new revenue for the company, but Q3’s miss on revenue had a lot to do with the need for discounting the drug ahead of Novo Nordisk’s rival therapy, Rybelsus, which was priced on the wholesale level at an almost identical rate.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 63,100+ biopharma pros reading Endpoints daily — and it's free.

No­var­tis hands off $80M in cash to part­ner up with a top biotech play­er in the fi­bro­sis sec­tor

Never underestimate the power of a good showing at a scientific conference.
In a presentation late last year, the researchers at Pliant Therapeutics launched a series of discussions about the preclinical data they were pulling together around their work on their small-molecule integrin inhibitor aimed at transforming growth factor beta, or TGF-β, a key pathway involved in fibrosis.
And they got some serious attention for the work.
“We got interest from pharma partners and at the end Novartis basically made it,” says Pliant CEO Bernard Coulie.

Is there a recipe for M&A suc­cess? The best and worst buy­out deals in the past decade of­fer some keys to suc­cess — and fail­ure

It’s not easy achieving a solid win in M&A in this industry. But if you follow a few simple guidelines, you may be able to increase your odds of success.
Geoffrey Porges and the team at SVB Leerink went about the “notoriously difficult” task of scoring the biopharma buyout of 2009 to 2019. Sizing up current and expected revenue from the products that were gained, they came up with the 5 winners:
Merck/Schering Plough
Bristol/Medarex
Gilead/Pharmasset
Sanofi/Genzyme
AstraZeneca/Acerta
It says a lot about the field that it’s much easier sorting out the 5 worst deals, though there’s also a lot more competition for that title, notes Porges. As picked by the analysts:
J&J/Actelion
Merck/Cubist
Alexion/Synageva
AbbVie/Stemcentrx
Gilead/Kite

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 63,100+ biopharma pros reading Endpoints daily — and it's free.